Pharmaceutical patent analyst

New Developments in Liraglutide: A Review of Patents from 2014 to 2024

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated

Abstract

Liraglutide, a GLP-1 agonist, is associated with effective regulation of blood glucose levels in type-2 diabetes mellitus.

  • Type-2 diabetes mellitus is characterized by insulin resistance and impaired glucose regulation.
  • GLP-1 mimetics like liraglutide show beneficial effects on blood glucose management.
  • Liraglutide is noted for its similarities to natural GLP-1 in function.
  • Clinical trials indicate the effectiveness of liraglutide in addressing complications related to type-2 diabetes.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Funding

Competing interests

The authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
PubMed

Related papers

Aug '20
Long-lasting GLP-1 receptor drugs: effectiveness, safety, and use in managing type 2 diabetes
cited by 39 papers
journal article
Feb '25
Liraglutide and new nano-sized delivery systems for better treatment
top 30% journal
cited by 3 papers
journal article
May '17
DPP-4 inhibitors and GLP-1 drugs for preventing or delaying type 2 diabetes and related health problems in high-risk people
cited by 27 papers
systematic review
Jan '17
Different glucagon-like peptide-1 drugs have varying effects on heart rate
top 2% journal
cited by 138 papers
research support, non-u.s. gov't
Oct '19
Glucagon-like peptide 1 receptor activators in type 1 diabetes
top 50% journal
cited by 53 papers
journal article

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
yesterday7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
1 week ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
2 weeks ago7 studies
issue #44
Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study
3 weeks ago7 studies
issue #43
Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients
4 weeks ago7 studies
issue #42
Tirzepatide users lost 14.7% of body weight vs. 10.8% with semaglutide — but Black and Hispanic patients were overrepresented in the lowest-response group
5 weeks ago8 studies
issue #41
New obesity drug survodutide cut weight by 13% vs 5.4% for placebo in 725 patients
6 weeks ago7 studies
issue #40
GLP-1 users had 3x higher risk of aspiration pneumonia after stroke surgery
7 weeks ago7 studies
issue #39
Semaglutide linked to reduced cigarette craving in 24 smokers
8 weeks ago7 studies
issue #38
Two-thirds of patients kept weight off after stopping GLP-1 drugs
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief